StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Evercore ISI on Cytokinetics (CYTK): 'positive edge' into topline Ph3 data
April 1, 2026 9:28 AM
Evercore ISI analyst Cory Kasimov reiterated an Outperform rating and $80.00 price target on Cytokinetics (NASDAQ: CYTK)The analyst commented, "CYTK’s ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
